Table 2. Outcomes and disease response... | American Society of Hematology

Table 2.

Outcomes and disease response

Patient no.	Follow-up: safety, mo	Change in EDSS from baseline, mo									Oligoclonal bands, before/after HDIT (mo of f/u)
Patient no.	Follow-up: safety, mo			1	3	6	12	24	36	Outcomes	Oligoclonal bands, before/after HDIT (mo of f/u)
1	47	0	0	0	0	+0.5	0	+/− (24)	—
2	45	0	NT	−2.5	−3.0	0	NT	−/− (24)	—
3	40	0	0	−0.5	−0.5	0	0	−/− (24)	—
4	38	+0.5	+1.0	−0.5	−0.5	−0.5	−0.5	−/− (12)	Flare of MS with stem cell mobilization
5	34	0	0	0	0	0	—	+/+ (12)	—
6^*	33	+0.5	+1.5	+0.5	+1.5	NT	—	+/− (12)	Progression of MS
7^*	33	0	+0.5	+1.0	+1.0	+2.0	—	+/+ (12)	Progression of MS
8†	30	−0.5	0	NT	NT	NT	—	−/− (3)	—
9	2	—	—	—	—	—	—	—	EBV-PTLD; died on day +53
10	29	0	0	0	0	0	—	+/+ (12)	—
11	29	0	0	0	+0.5	0	—	+/+ (12)	ITP; at day 60
12^*	29	0	0	0	0	+1.0	—	+/+ (12)	Progression of MS
13	28	−0.5	0	0	0	+0.5	—	−/− (12)	Hypothyroidism
14^*	28	0	−0.5	0	+0.5	+1.0	—	+/+ (12)	Neuropathy/hypothermia, at month 17; progression of MS
15	27	+0.5	0	+0.5	+0.5	0	—	−/− (12)	Brachial neuritis, at day 30
16^*	23	+1.0	+1.0	+1.0	+1.0	NT	—	−/+ (3)	Progression of MS; died at month 23
17	27	+0.5	0	NT	0	+0.5	—	+/NE (3)	—
18	26	0	−0.5	−0.5	0	0	—	+/+ (3)	—
19	26	+1.5	0	−0.5	−0.5	+0.5	—	+/+ (12)	—
20	24	−0.5	−0.5	−0.5	−0.5	0	—	+/+ (12)	—
21	23	−0.5	−1.0	−0.5	0	0	—	+/− (12)	—
22	22	0	0	−0.5	−0.5	—	—	NT	—
23	18	NT	0	+0.5	0	—	—	NT	—
24^*	18	0	+1.0	+1.0	+1.0	—	—	−/− (3)	Progression of MS
25†	17	0	0	NT	NT	—	—	+/NT	—
26	15	0	0	0	0	—	—	−/− (3)	—

Patient no.	Follow-up: safety, mo	Change in EDSS from baseline, mo									Oligoclonal bands, before/after HDIT (mo of f/u)
Patient no.	Follow-up: safety, mo			1	3	6	12	24	36	Outcomes	Oligoclonal bands, before/after HDIT (mo of f/u)
1	47	0	0	0	0	+0.5	0	+/− (24)	—
2	45	0	NT	−2.5	−3.0	0	NT	−/− (24)	—
3	40	0	0	−0.5	−0.5	0	0	−/− (24)	—
4	38	+0.5	+1.0	−0.5	−0.5	−0.5	−0.5	−/− (12)	Flare of MS with stem cell mobilization
5	34	0	0	0	0	0	—	+/+ (12)	—
6^*	33	+0.5	+1.5	+0.5	+1.5	NT	—	+/− (12)	Progression of MS
7^*	33	0	+0.5	+1.0	+1.0	+2.0	—	+/+ (12)	Progression of MS
8†	30	−0.5	0	NT	NT	NT	—	−/− (3)	—
9	2	—	—	—	—	—	—	—	EBV-PTLD; died on day +53
10	29	0	0	0	0	0	—	+/+ (12)	—
11	29	0	0	0	+0.5	0	—	+/+ (12)	ITP; at day 60
12^*	29	0	0	0	0	+1.0	—	+/+ (12)	Progression of MS
13	28	−0.5	0	0	0	+0.5	—	−/− (12)	Hypothyroidism
14^*	28	0	−0.5	0	+0.5	+1.0	—	+/+ (12)	Neuropathy/hypothermia, at month 17; progression of MS
15	27	+0.5	0	+0.5	+0.5	0	—	−/− (12)	Brachial neuritis, at day 30
16^*	23	+1.0	+1.0	+1.0	+1.0	NT	—	−/+ (3)	Progression of MS; died at month 23
17	27	+0.5	0	NT	0	+0.5	—	+/NE (3)	—
18	26	0	−0.5	−0.5	0	0	—	+/+ (3)	—
19	26	+1.5	0	−0.5	−0.5	+0.5	—	+/+ (12)	—
20	24	−0.5	−0.5	−0.5	−0.5	0	—	+/+ (12)	—
21	23	−0.5	−1.0	−0.5	0	0	—	+/− (12)	—
22	22	0	0	−0.5	−0.5	—	—	NT	—
23	18	NT	0	+0.5	0	—	—	NT	—
24^*	18	0	+1.0	+1.0	+1.0	—	—	−/− (3)	Progression of MS
25†	17	0	0	NT	NT	—	—	+/NT	—
26	15	0	0	0	0	—	—	−/− (3)	—

Neurologic assessment and scoring of EDSS was done at scheduled visits at 1, 3, 6, 12, 24, and 36 months. MRI results are changes from baseline at last scheduled study. mo indicates month; f/u, follow-up; NT, not tested; —, no data; and NE, not evaluable.

Determined to have progressed.

†

Lost to follow-up.

View Large

This Feature Is Available To Subscribers Only